openPR Logo
Press release

Fungal Antigens Market Segmentation By product type Aspergillus Antigen, Candida albicans Antigen, Saccharomyces Antigen, A. caninum NIF, S. pombe RNA1P, S. pombe RNA; By pathogen type Inactivated Pathogen, Purified Pathogen; By application type Immunohis

04-18-2019 09:55 AM CET | Advertising, Media Consulting, Marketing Research

Press release from: Fact.MR

Fungal Antigens Market Segmentation By product type

Antigens, commonly, are referred to as substances that are capable of triggering an immune response in a host, precisely by activating the lymphocytes or initiating antibody production against the infection. Depending upon the fact that they either enter the human body or originate within the body, these fungal antigens are classified as foreign or self-antigens. Among these, the self-antigens comprise of mutated or overexpressed proteins. However, foreign antigens may include fungus, bacteria, parasites, viruses, chemicals, and sometimes toxins & proteins found in food products.

A wide range of fungal species of Aspergillus and other fungal organisms play important roles in the pharmacy and healthcare industry. For instance, some of the Aspergillus species play vital roles in commercial microbial fermentations and are also involved in the production of foreign or native enzymes. These fungal species can cause infections in humans. A range of fungal diseases in humans include infections of the ear, external skin wounds and ulcers. Other fungal species also act as raw material sources that can be used to develop medications. Owing to increased applications of fungal antigens to diagnose various fungal infections for clinical research purposes, a large number of local manufacturers have expanded their product portfolio of fungal pathogens intended for academic as well as industrial applications.

Fungal antigens in the fungal antigens market are commercially available in distinct formats, which include purified and inactivated pathogens. A wide range of native state fungal antigens are highly in demand, particularly for in-vitro diagnostics. Standard properties recommended for apt fungal antigens include higher specificity & sensitivity, simple production & quality control and the capability of a fungal antigen to carry out early diagnosis of fungal infection in order to get effective treatment. Under the product type segment defined for the fungal antigens market, the Aspergillus antigen accounts for a significant revenue share in the global fungal antigens market followed by the Saccharomyces fungal antigen. On the account of their usage as reagents to diagnose fungal diseases, fungal antigens are of great interest. These fungal antigens find applications in various diagnostic techniques, which include Immunohistochemistry (IHC), Polymerase chain reaction (PCR), In-situ hybridization (ISH) and SDS-PAGE in the fungal antigens market. They also find major applications to carry out immunological tests to diagnose mycotic infections. With the growing incidence of fungal diseases, there is an urgent need to create sensitive, commercially available and reliable tests to diagnose the opportunistic fungal pneumonias. The major potential end users for the fungal antigens market, where these antigens are highly in demand and generate significant revenues, include hospitals, associated diagnostic laboratories, diagnostic laboratories & centres and academic & research institutes.

Request Free Sample Report@ https://www.factmr.com/connectus/sample?flag=S&rep_id=1773

Fungal Antigens Market: Drivers and Restraints

The growing demand for fungal antigens indicated for fungal antigens that are capable of eliciting a protective immune response against various cancers and infectious diseases such as HIV AIDS is expected to be a major factor driving the fungal antigens market over the forecast period. Also, rapid discovery of novel fungal antigens, growing incidence of cancers & infectious diseases and increase in diagnostic population for variant diseases is also expected to drive the revenue growth of the global fungal antigens market. Also, increasing prevalence of infections caused by fungal pathogens and changing climatic conditions leading to increased incidence of fungal infections is expected to generate revenue opportunities for the fungal antigens market. The approval and launch of new fungal antigens is the other important factor contributing to the growth of the global fungal antigens market. However, increasing risk of adverse reactions with antigens is restraining the revenue growth of the global fungal antigens market.

Fungal Antigens Market: Segmentation

Tentatively, the global fungal antigens market can be segmented on the basis of product type, pathogen type, application, end user and geography.

Based on product type, the global fungal antigens market is segmented as:

Aspergillus Antigen
aculeatus Pectolyase Y-23
Aspergillus Giganteus AF Protein
Aspergillus Restrictus Restrictocin
Aspergillus Giganteus Alpha-Sarcin
Aspergillus fumigatus Antigen
Candida albicans Antigen
Saccharomyces Antigen
A. caninum NIF
S. pombe RNA1P
S. pombe RNA

Request/View TOC@ https://www.factmr.com/connectus/sample?flag=T&rep_id=1773

Based on pathogen type, the global fungal antigens market is segmented as:

Inactivated Pathogen
Purified Pathogen
Based on application type, the global fungal antigens market is segmented as:

Immunohistochemistry (IHC)
Polymerase chain reaction (PCR)
In-situ hybridization(ISH)
SDS-PAGE
Based on end user, the global fungal antigens market is segmented as:

Hospital Associated Diagnostic Laboratories
Diagnostic Laboratories and Centres
Academic and Research Institutes
Fungal Antigens Market: Overview

The global market for fungal antigens is expected to register a moderate growth rate over the forecast period owing to significant investments to introduce innovative tests to capitalise on the opportunities in the untapped market. According to a study conducted by CDC, histoplasmosis is registered as significant infection in patients with HIV and AIDS. Late diagnosis leading to the delayed treatment of the disease can prove fatal, hence, the need for fungal antigens is on rise. Recently, different types of fungal antigens are being introduced in the fungal antigens market by the leading players, which include Bio-Rad Laboratories, Inc. and Creative Diagnostics. There is high competition among local and regional players in the fungal antigens market. Among the fungal antigens type indicated for various diagnostic applications, the Aspergillus antigen segment is expected to lead the global fungal antigens market over the forecast period. Diagnostic laboratories and centres are expected to contribute a high revenue share in the global fungal antigens market as they are the most significant platforms to perform diagnostic tests and generate high demand for fungal antigens. Hospital-associated diagnostic laboratories also account for significant revenue generation owing to a large number of patients wanting to get diagnosed.

Fungal Antigens Market: Regional Outlook

Geographically, the global fungal antigens market is segmented into North America, Latin America, Europe, CIS & Russia, Asia-Pacific Excluding Japan, Japan and the Middle East & Africa. North America is registered as the dominant market player in global fungal antigens market on the account of growing research applications of fungal antigens along with increased set up of advanced diagnostic laboratories in the region as compared to other regions. The fungal antigens market in Asia Pacific excluding Japan is expected to grow at the highest CAGR due to a strong foothold of domestic players manufacturing fungal antigens. Europe is expected to register the second largest revenue share in the global fungal antigens-market throughout the forecast period owing to the increased presence of distributors and suppliers for fungal antigens across the region.

Fungal Antigens Market: Key Players

The global fungal antigens market is highly fragmented owing to presence of a large number of domestic manufacturers. Examples of some of the key players operating in the global fungal antigens market are Bio-Rad Laboratories, Inc., Creative Diagnostics, IMMY, QED Bioscience Inc., Pulse Scientific Inc. and Jena Bioscience GmbH.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

The report covers exhaustive analysis on:

Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain
Regional analysis includes

North America (U.S., Canada)
Latin America (Mexico, Brazil, Argentina, Chile, Peru, and Rest of Latin America)
Europe [EU -4 (Germany, France, Italy, Spain), BENELUX (Belgium, Netherlands, Luxemburg), NORDIC (Norway, Denmark, Iceland, Sweden), Eastern Europe (Poland, Ukraine, Czech Rep. etc.), Rest of Europe
CIS & Russia
Japan
APEJ (Greater China, India, S. Korea, ASEAN Countries and Rest of APEJ)
Middle East & Africa (GCC Countries, Turkey, Iran, Israel, South Africa, Rest of MEA)
Report Highlights:

Detailed overview of parent market
Changing market dynamics in the industry
In-depth market segmentation
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint.

Report Analysis@ https://www.factmr.com/report/1773/fungal-antigens-market

About US
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
Rohit Bhisey
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Blog: https://factmrblog.com/
Read Industry News at - http://theguardiantribune.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Fungal Antigens Market Segmentation By product type Aspergillus Antigen, Candida albicans Antigen, Saccharomyces Antigen, A. caninum NIF, S. pombe RNA1P, S. pombe RNA; By pathogen type Inactivated Pathogen, Purified Pathogen; By application type Immunohis here

News-ID: 1708662 • Views: 149

More Releases from Fact.MR

Tea Infusion Market to Record Sturdy Growth by 2032
The New Report "Tea Infusion Market" published by Fact.MR, covers the competitive landscape analysis and its growth prospects over the coming years. An in-depth study of some new and prominent industry trends, analysis of engagement, and regional analysis that is very detailed have been included in the report of the Tea Infusion market for the analysis period of 2022 - 2032. Get In-depth Insights Request for Brochure here: https://www.factmr.com/connectus/sample?flag=B&rep_id=4157 Through the
Glufosinate Market to See Incredible Growth during Forecast 2032
The New Report "Glufosinate Market" published by Fact.MR, covers the competitive landscape analysis and its growth prospects over the coming years. An in-depth study of some new and prominent industry trends, analysis of engagement, and regional analysis that is very detailed have been included in the report of the Glufosinate market for the analysis period of 2022 - 2032. Get In-depth Insights Request for Brochure here: https://www.factmr.com/connectus/sample?flag=B&rep_id=4144 Through the new research
Point Of Sale (POS) Terminals Market Is Expected To Be Valued At US$ 85 Bn In 20 …
The point of sale (POS) terminals market has garnered a market value of US$ 85 Bn in 2022, anticipated to register a positive CAGR of 7.8% in the forecast period 2022-2032 and reach a value of US$ 180.13 Bn. The report offers actionable and valuable market insights of Mobile Point of Sale (POS) Terminals. The latest report by Fact.MR provides details on the present scenario of the market across various
Marine Filter Market set to record exponential growth by 2032
The New Report "Marine Filter Market" published by Fact.MR, covers the competitive landscape analysis and its growth prospects over the coming years. An in-depth study of some new and prominent industry trends, analysis of engagement, and regional analysis that is very detailed have been included in the report of the Marine Filter market for the analysis period of 2022 - 2032. Get In-depth Insights Request for Brochure here: https://www.factmr.com/connectus/sample?flag=B&rep_id=4140 Through the

All 5 Releases


More Releases for Antigen

New HGH Saliva Antigen Covid Test gamechanger
An Austrian company HGH Disinfection und Cosmetique Gmbh, based in 9020 Klagenfurt created with a Korean partner a unique antigen salvia test unit which is so simple that anybody can use it. Till now mass testing was nasal stick by government and doctors. Now this new test unit can be used by everybody without a scarry stick in the nose and a result with 95% is ready in 10
p53 Antigen Modulators Therapeutics- Pipeline Analysis 2018 |
p53 is the tumor suppressor transcription factor that activates to various stimulus, including uncontrolled cell proliferation, oncogene over-expression, and DNA damage. p53 antigen modulators helps in preventing cancer development through regulation of cell cycle and apoptosis. Download the sample report @ https://www.pharmaproff.com/request-sample/1195 Thus, new opportunities in cancer immunotherapy are expected to develop better drug candidates targeting p53, with complete understanding of interactions between p53 and the immune system, to avoid various
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Anti …
ReportsWorldwide has announced the addition of a new report title Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) also
CancerTestis Antigen 1 (Autoimmunogenic CancerTestis Antigen NY ESO 1 or CancerT …
ReportsWorldwide has announced the addition of a new report title CancerTestis Antigen 1 (Autoimmunogenic CancerTestis Antigen NY ESO 1 or CancerTestis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) -
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Anti …
Market Research Hub (MRH) added a new research report to its vast database titled “Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Pipeline Review, H2 2017” targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Carcinoembryonic Antigen Related Cell Adhesion
B-Cell Maturation Antigen Targeted Therapies Market
Multiple myeloma is an incurable disease of plasma cells, which needs some intervention by clinical researchers. However, there have been recent success in developing such therapy that can be effective in hematologic malignancies such as chimeric antigen receptor CAR-T cell therapy, which is expected to be promising in cancer treatment. However, researchers have found little success in finding a specific target antigen under CAR T-cell therapies for treating multiple myeloma.